Profusa, Inc. (PFSA) 株式分析

企業概要

Profusa, Inc. is a healthcare enterprise focused on the medical devices sector, specifically developing bioengineered sensors designed to detect and continuously transmit clinical-grade data for personal and medical applications in the United States. The company's core product offering, the Lumee Oxygen Platform, targets specific medical indications including the monitoring of compromised tissue associated with peripheral artery disease, chronic wounds, and reconstructive surgery procedures. In terms of scale, Profusa, Inc. currently holds a market capitalization of $1.66M while reporting zero revenue and having no publicly disclosed employee count in the available data. These valuation and revenue figures indicate that the company operates as a micro-cap entity with a significant investment in research and development or operational scaling that has not yet translated into commercial revenue generation. The absence of reported revenue alongside a sub-$2M market cap suggests the company is in a pre-revenue or early-stage commercialization phase where market capitalization reflects investor expectations for future product adoption rather than current operational earnings.

財務健全性

The company reported zero revenue over the trailing twelve-month period, resulting in a net income loss of $-29,508,000, while EBITDA data is not available for this reporting period. The substantial gap between zero revenue and a significant net income loss reveals a cost structure dominated by high operating expenses, likely comprising research and development costs, administrative overhead, or manufacturing setup costs that exceed any current sales volume. Free cash flow stands at $-10,704,875, indicating that the company is burning through its liquidity reserves to fund operations and strategic initiatives rather than generating positive cash flow from its business activities. Regarding profitability metrics, the gross margin, operating margin, and profit margin are all recorded at 0.0%, which is typical for a company with no sales but underscores that the company is not yet generating revenue to cover its variable or fixed costs. The balance sheet shows a cash position of $3.01M against total debt of $21.07M, creating a situation where liabilities exceed liquid assets, and the debt-to-equity ratio is not available, likely due to the lack of book equity or specific accounting classifications for this micro-cap. The current ratio is 0.18, which signifies a severe liquidity constraint as current liabilities are more than five times greater than current assets, suggesting an inability to meet short-term obligations without additional financing. Return on Equity is not available, whereas Return on Assets is reported at -465.1%, indicating that the company's asset base is generating substantial negative returns relative to its equity, reflecting the heavy investment in assets that have not yet produced income.

バリュエーション評価

Trailing P/E and forward P/E ratios are not available due to the company's lack of earnings, meaning traditional earnings-based valuation multiples cannot be calculated or imply infinite valuations. The price-to-book ratio is listed as -0.02, a negative figure that typically indicates the market is valuing the company's equity at a discount to its book value or reflects negative shareholder equity on the balance sheet. Since the company has no revenue, the price-to-sales ratio is infinite, and EV/EBITDA is not available, these alternative valuation metrics suggest that investors are pricing the stock based on potential future milestones rather than current financial performance or sales traction. The stock has traded within a wide range over the past year, with a 52-week high of $412.50 and a 52-week low of $0.41. Given the vast disparity between these highs and lows, the current trading price sits extremely close to the bottom of this range, reflecting significant market skepticism regarding the company's ability to monetize its technology at the scale required to justify a higher share price. The beta value is 0.26, which indicates that the stock price exhibits very low volatility relative to the broader market, moving less than one-third as much as the overall market index and behaving more like a low-beta asset despite its high-risk fundamental profile.

Growth & Income

Revenue growth and earnings growth rates are not available for the trailing twelve months or year-over-year comparisons, precluding any analysis of whether earnings are growing faster or slower than revenue. The company does not pay a dividend, as indicated by a dividend yield of not available and a payout ratio of 0.0%. Consequently, the company reinvests its remaining resources, if any, or seeks external capital to fund its growth initiatives rather than distributing income to shareholders. Since the company generates no profit to distribute, the lack of dividends is a structural necessity rather than a strategic choice, forcing the firm to rely on equity issuance or debt financing to sustain its operations. The overall growth and income profile is characterized by a complete absence of historical earnings, zero dividend income, and infinite sales growth rates that are currently theoretical rather than realized, presenting a high-risk, high-potential-return scenario where returns are contingent on the successful commercialization of the Lumee Oxygen Platform.